Lifemd, Inc. ( (LFMD) ) has released its Q1 earnings. Here is a breakdown of the information Lifemd, Inc. presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
LifeMD, Inc. is a prominent provider of virtual primary care services, offering telemedicine, laboratory, and pharmacy services across a wide range of health conditions. The company operates in the telehealth industry, leveraging a proprietary digital care platform to deliver accessible and affordable healthcare solutions.
In its first quarter of 2025, LifeMD reported a significant increase in total revenues, up 49% year-over-year to $65.7 million, with telehealth revenue surging by 70%. The company achieved its first-ever quarter of positive GAAP net income, marking a milestone in its financial performance.
Key financial highlights include an adjusted EBITDA increase to $8.7 million from $0.1 million in the previous year, and a telehealth adjusted EBITDA of $5.3 million, reversing a loss of $1.3 million from the prior year. The company also reported a net income of $0.6 million or $0.01 per diluted share. LifeMD’s strategic collaborations and new service offerings, such as men’s hormone therapy and Medicare acceptance, have contributed to its robust growth.
Looking ahead, LifeMD has raised its full-year 2025 guidance, expecting total revenues between $268 million and $275 million, and adjusted EBITDA between $31 million and $33 million. This upward revision reflects the company’s strong performance and growth trajectory in the telehealth sector.
LifeMD’s management remains optimistic about the company’s future, focusing on expanding its service offerings and strategic partnerships to meet the growing demand for telehealth services.